Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

FDA Committee Voted 8-5 That Known Potential Benefits Do Not Outweigh The Known And Potential Risks Of Sabizabulin. Input Of The Advisory Committee As Part Of Their Review Of The EUA And Render A Decision On The Emergency Use Authorization

Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, announces the results of today's meeting of the U.S.

VERU